Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial

D. E. Fleischer; B. F. Overholt; V. K. Sharma; A. Reymunde; M. B. Kimmey; R. Chuttani; K. J. Chang; R. Muthasamy; C. J. Lightdale; N. Santiago; D. K. Pleskow; P. J. Dean; K. K. Wang

doi:10.1055/s-0030-1255779

Endoscopy 2010; 42(10): 781-789
DOI: 10.1055/s-0030-1255779

Original article

Endoscopic radiofrequency ablation for Barrett’s esophagus: 5-year outcomes from a prospective multicenter trial[*]

D. E. Fleischer¹ , B. F. Overholt² , V. K. Sharma¹ , A. Reymunde³ , M. B. Kimmey⁴ , R. Chuttani⁵ , K. J. Chang⁶ , R. Muthasamy⁶ , C. J. Lightdale⁷ , N. Santiago³ , D. K. Pleskow⁵ , P. J. Dean⁸ , K. K. Wang⁹

¹Mayo Clinic, Scottsdale, Arizona, USA
²Gastrointestinal Associates, Knoxville, Tennessee, USA
³Ponce Gastroenterology, Ponce, Puerto Rico, USA
⁴Tacoma Digestive Disease Center, Tacoma, Washington, USA
⁵Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
⁶University California, Irvine, California, USA
⁷Columbia Presbyterian Medical Center, New York, USA
⁸GI Pathology, Memphis, Tennessee, USA
⁹Mayo Clinic, Rochester, Minnesota, USA

Abstract

Background and study aims: The AIM-II Trial included patients with nondysplastic Barrett’s esophagus (NDBE) treated with radiofrequency ablation (RFA). Complete eradication of NDBE (complete response-intestinal metaplasia [CR-IM]) was achieved in 98.4 % of patients at 2.5 years. We report the proportion of patients demonstrating CR-IM at 5-year follow-up.

Patients and methods: Prospective, multicenter US trial (NCT00489268). After endoscopic RFA of NDBE up to 6 cm, patients with CR-IM at 2.5 years were eligible for longer-term follow-up. At 5 years, we obtained four-quadrant biopsies from every 1 cm of the original extent of Barrett’s esophagus. All specimens were reviewed by one expert gastrointestinal pathologist, followed by focal RFA and repeat biopsy if NDBE was identified. Primary outcomes were (i) proportion of patients demonstrating CR-IM at 5-year biopsy, and (ii) proportion of patients demonstrating CR-IM at 5-year biopsy or after the single-session focal RFA.

Results: Of 60 eligible patients, 50 consented to participate. Of 1473 esophageal specimens obtained at 5 years 85 % contained lamina propria or deeper tissue (per patient, mean 30 [13], standard deviation [SD] 13). CR-IM was demonstrated in 92 % (46 / 50) of patients, while 8 % (4 / 50) had focal NDBE; focal RFA converted all these to CR-IM. There were no buried glands, dysplasia, strictures, or serious adverse events. Kaplan-Meier CR-IM survival analysis showed probability of maintaining CR-IM for at least 4 years after first durable CR-IM was 0.91 (95 % confidence interval [CI] 0.77 – 0.97) and mean duration of CR-IM was 4.22 years (standard error [SE] 0.12).

Conclusions: In patients with NDBE treated with RFA, CR-IM was demonstrated in the majority of patients (92 %) at 5-year follow-up, biopsy depth was adequate to detect recurrence, and all failures (4 / 4, 100 %) were converted to CR-IM with single-session focal RFA.

Volltext

Referenzen

References

1 Haggitt R C. Barrett's esophagus: pathogenesis, dysplasia, and adenocarcinoma. Hum Pathol. 1994; 25 982-993
2 Winters Jr. C, Spurling T J, Chobanian S J. et al . Barrett’s esophagus: a prevalent, occult complication of gastroesophageal reflux disease. Gastroenterology. 1987; 92 118-124
3 Wang K K, Sampliner R E. Updated Guidelines 2008 for the diagnosis, surveillance and therapy of barrett’s esophagus. Am J Gastroenterol. 2008; 103 788-797
4 Sharma P, McQuaid K, Dent J. et al . A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004; 127 310-330
5 Watson A, Heading R C, Shepherd N A. Guidelines for the diagnosis and management of Barrett’s columnar-lined oesophagus: a report of the Working Party of the British Society of Gastroenterology. London; British Society of Gastroenterology 2005
6 Boyer J, Laugier R, Chemali M. et al . French Society of Digestive Endoscopy SFED guideline: monitoring of patients with Barrett’s esophagus. Endoscopy. 2007; 39 840-842
7 Society for Surgery of the Alimentary Tract . SSAT patient care guidelines. Management of Barrett’s esophagus. J Gastrointest Surg. 2007; 11 1213-1215
8 Inadomi J M. Surveillance in Barrett’s esophagus: a failed premise. Keio J Med. 2009; 58 12-18
9 Shaheen N J, Provenzale D, Sandler R S. Upper endoscopy as a screening and surveillance tool in esophageal adenocarcinoma: a review of the evidence. Am J Gastroenterol. 2002; 97 1319-1327
10 Montgomery E, Bronner M P, Goldblum J R. et al . Reproducibility of the diagnosis of dysplasia in Barrett esophagus: a reaffirmation. Hum Pathol. 2001; 32 368-378
11 Reid B J, Haggitt R C, Rubin E C. et al . Observer variation in the diagnosis of dysplasia in Barrett’s esophagus. Human Pathol. 1988; 19 166-178
12 Alikhan M, Rex D, Khan A. et al . Variable pathologic interpretation of columnar lined esophagus by general pathologists in community practice. Gastrointest Endosc. 1999; 50 23-26
13 Abrams J A, Kapel R C, Lindberg G M. et al . Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin Gastroenterol Hepatol. 2009; 7 736-742
14 Fleischer D E, Overholt B F, Sharma V K. et al . Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008; 68 867-876
15 Dulai G S, Jensen D M, Cortina G. et al . Randomized trial of argon plasma coagulation vs. multipolar electrocoagulation for ablation of Barrett’s esophagus. Gastrointest Endosc. 2005; 61 232-240
16 Fitzgerald R C. Complex diseases in gastroenterology and hepatology: GERD, Barrett’s, and esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2005; 3 529-537
17 Rabinovitch P S, Longton G, Blount P L. et al . Predictors of progression in Barrett’s esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001; 96 3071-3083
18 Reid B J, Levine D S, Longton G. et al . Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000; 95 1669-1676
19 Wijnhoven B P, Hussey D J, Watson D I. et al . MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg. 2010; 97 853-861
20 Huang Q, Hardie L J. Biomarkers in Barrett’s oesophagus. Biochem Soc Trans. 2010; 38 343-347
21 Wani S, Puli S R, Shaheen N J. et al . Esophageal adenocarcinoma in Barrett’s esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol. 2009; 104 502-513
22 Sharma P, Falk G W, Weston A P. et al . Dysplasia and cancer in a large multicenter cohort of patients with Barrett’s esophagus. Clin Gastroenterol Hepatol. 2006; 4 566-572
23 Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett’s esophagus?. Gastroenterology. 2000; 119 333-338
24 Anderson L A, Murray L J, Murphy S J. et al . Mortality in Barrett’s oesophagus: results from a population based study. Gut. 2003; 52 1081-1084
25 Sharma V K, Wang K K, Overholt B F. et al . Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett’s esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc. 2007; 65 185-195
26 Shaheen N J, Sharma P, Overholt B F. et al . Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med. 2009; 360 2277-2288
27 Pouw R E, Wirths K, Eisendrath P. et al . Efficacy of radiofrequency ablation combined with endoscopic resection for Barrett’s esophagus with early neoplasia. Clin Gastroenterol Hepatol. 2010; 8 23-29
28 Lyday W D, Corbett F S, Kuperman D A. et al . Radiofrequency ablation of Barrett’s esophagus: outcomes of 429 patients from a multicenter community practice registry. Endoscopy. 2010; 42 272-278
29 dos Santos R S, Bizekis C, Ebright M. et al . Radiofrequency ablation for Barrett’s esophagus and low-grade dysplasia in combination with an antireflux procedure: a new paradigm. J Thorac Cardiovasc Surg. 2010; 139 713-716
30 Velanovich V. Endoscopic endoluminal radiofrequency ablation of Barrett’s esophagus: initial results and lessons learned. Surg Endosc. 2009; 23 2175-2180
31 Sharma V K, Kim H J, Das A. et al . Circumferential and focal ablation of Barrett’s esophagus containing dysplasia. Am J Gastroenterol. 2009; 104 310-317
32 Eldaif S M, Lin E, Singh K A. et al . Radiofrequency ablation of Barrett’s esophagus: short-term results. Ann Thorac Surg. 2009; 87 405-410
33 Pouw R E, Gondrie J J, Sondermeijer C M. et al . Eradication of Barrett esophagus with early neoplasia by radiofrequency ablation, with or without endoscopic resection. J Gastrointest Surg. 2008; 12 1627-1636
34 Ganz R A, Overholt B F, Sharma V K. et al . Circumferential ablation of Barrett’s esophagus that contains high-grade dysplasia: a U.S. multicenter registry. Gastrointest Endosc. 2008; 68 35-40
35 Gondrie J J, Pouw R E, Sondermeijer C M. et al . Stepwise circumferential and focal ablation of Barrett’s esophagus with high-grade dysplasia: results of the first prospective series of 11 patients. Endoscopy. 2008; 40 359-369
36 Gondrie J J, Pouw R E, Sondermeijer C M. et al . Effective treatment of early Barrett’s neoplasia with stepwise circumferential and focal ablation using the HALO system. Endoscopy. 2008; 40 370-379
37 Sharma V K, Kim H J, Das A. et al . A prospective pilot trial of ablation of Barrett’s esophagus with low-grade dysplasia using stepwise circumferential and focal ablation (HALO system). Endoscopy. 2008; 40 380-387
38 Hernandez J C, Reicher S, Chung D. et al . Pilot series of radiofrequency ablation of Barrett’s esophagus with or without neoplasia. Endoscopy. 2008; 40 388-392
39 Roorda A K, Marcus S N, Triadafilopoulos G. Early experience with radiofrequency energy ablation for Barrett’s esophagus with and without dysplasia. Dis Esophagus. 2007; 20 516-522
40 Hubbard N, Velanovich V. Endoscopic endolumenal radiofrequency ablation of Barrett’s esophagus in patients with fundoplication. Surg Endosc. 2007; 21 625-628
41 Wani S, Sayana H, Sharma P. Endoscopic eradication of Barrett’s esophagus. Gastrointest Endosc. 2010; 71 147-166
42 Basu K K, Pick B, Bale R. et al . Efficacy and one year follow up of argon plasma coagulation therapy for ablation of Barrett’s oesophagus: factors determining persistence and recurrence of Barrett’s epithelium. Gut. 2002; 51 776-780
43 Sharma P, Bhattacharyya A, Garewal H S. et al . Durability of new squamous epithelium after endoscopic reversal of Barrett’s esophagus. Gastrointest Endosc. 1999; 50 159-164
44 Overholt B F, Wang K K, Burdick J S. et al . Five-year safety and efficacy of photodynamic therapy with Photofrin in Barrett’s high-grade dysplasia. Gastrointest Endosc. 2007; 66 460-468
45 Inadomi J M, Somsouk M, Madanick R D. et al . A cost-utility analysis of ablative therapy for Barrett’s esophagus. Gastroenterology. 2009; 136 2101-2114
46 Das A, Wells C, Kim H J. et al . An economic analysis of endoscopic ablative therapy for management of nondysplastic Barrett’s esophagus. Endoscopy. 2009; 41 400-408
47 Ban S, Mino M, Nishioka N S. et al . Histopathologic aspects of photodynamic therapy for dysplasia and early adenocarcinoma arising in Barrett’s esophagus. Am J Surg Pathol. 2004; 28 1466-1473
48 Sharma P, Morales T G, Bhattacharyya A. et al . Squamous islands in Barrett’s esophagus: what lies underneath?. Am J Gastroenterol. 1998; 93 332-335
49 Shaheen N J, Goldblum J R, Sampliner R E. et al . Are biopsies after ablation for dysplastic Barrett’s esophagus of adequate depth to detect glandular mucosa beneath the neosquamous epithelium? Comparative histopathological outcomes from a randomized, sham-controlled trial (AIM Dysplasia Trial). Gastroenterology. 2008; 134 A-724

1 An oral presentation of this work was given at the American Society for Gastrointestinal Endoscopy (ASGE) Presidential Plenary Session at Digestive Diseases Week (DDW) 2010.

D. E. FleischerMD

Mayo Clinic, Scottsdale

13400 East Shea Boulevard
Scottsdale, AZ 85259-5499
USA

Fax: +1-480-301-8673

eMail: Fleischer.David@mayo.edu